Beyond Air (XAIR) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.Need a quote from one of our analysts? Email pr@fool.comBeyond Air (NASDAQ:XAIR) reported substantial GAAP revenue growth for FY2025, driven primarily by new and renewed U.S. hospital contracts for its LungFit platform, and signaled increased commercial activity through aggressive operating expense reductions. Management introduced significant revenue guidance for the upcoming fiscal year and outlined U.S. and international market expansion strategies, supplemented by progress toward FDA approval for the LungFit PH2 device and strategic partnerships in more than ten new global markets. Research and development expenses decreased from $24.4 million in FY2024 to $16.9 million in FY2025, while the organization's pipeline divisions -- Beyond Cancer and Neuronass -- advanced with clinical milestones and external funding, highlighting portfolio diversification across rare disease and oncology therapeutics.Continue reading
Image source: The Motley Fool.
Need a quote from one of our analysts? Email pr@fool.com
Beyond Air (NASDAQ:XAIR) reported substantial GAAP revenue growth for FY2025, driven primarily by new and renewed U.S. hospital contracts for its LungFit platform, and signaled increased commercial activity through aggressive operating expense reductions. Management introduced significant revenue guidance for the upcoming fiscal year and outlined U.S. and international market expansion strategies, supplemented by progress toward FDA approval for the LungFit PH2 device and strategic partnerships in more than ten new global markets. Research and development expenses decreased from $24.4 million in FY2024 to $16.9 million in FY2025, while the organization's pipeline divisions -- Beyond Cancer and Neuronass -- advanced with clinical milestones and external funding, highlighting portfolio diversification across rare disease and oncology therapeutics.
